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Abstract
Background: Data available on the immunomodulatory properties of neural stem/precursor cells (NPC) support their
possible use as modulators for immune-mediated process. The aim of this study was to define whether NPC administered in
combination with pancreatic islets prevents rejection in a fully mismatched allograft model.
Methodology/Principal Finding: Diabetic Balb/c mice were co-transplanted under the kidney capsule with pancreatic islets
and GFP
+ NPC from fully mismatched C57BL/6 mice. The following 4 groups of recipients were used: mice receiving islets
alone; mice receiving islets alone and treated with standard immunosuppression (IL-2Ra chain mAbs + FK506 + Rapamycin);
mice receiving a mixed islet/NPC graft under the same kidney capsule (Co-NPC-Tx); mice receiving the islet graft under the
left kidney capsule and the NPC graft under the right kidney capsule (NPC-Tx). Our results demonstrate that only the co-
transplantation and co-localization of NPC and islets (Co-NPC-Tx) induce stable long-term graft function in the absence of
immunosuppression. This condition is associated with an expansion of CD4
+CD25
+FoxP3
+ T regulatory cells in the spleen.
Unfortunately, stable graft function was accompanied by constant and reproducible development of NPC-derived cancer
mainly sustained by insulin secretion.
Conclusion: These data demonstrate that the use of NPC in combination with islets prevents graft rejection in a fully
mismatched model. However, the development of NPC-derived cancer raises serious doubts about the safety of using adult
stem cells in combination with insulin-producing cells outside the original microenvironment.
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Introduction
Adult multipotent neural stem/precursor cells (NPC) are
broadly proposed as an alternative cell source to repair brain
damage upon transplantation and NPC-driven brain repair has
variably been shown in several pre-clinical models of neurolog-
ical disorders [1,2]. While the replacement of lost or damaged
cells was until a few years ago assumed to be the prime
therapeutic mechanism of stem cell, it is now clear that
transplanted NPC may simultaneously instruct several mecha-
nisms not confined to cell replacement on its own [1]. In
experimental autoimmune encephalomyelitis models, NPC exert
immune-like functions and induce apoptosis of blood-borne
encephalitogenic T cells [3–6], as well as decrease CNS
inflammation via peripheral suppression of the adaptive immune
response [6–8]. In an intracerebral haemorrhage model, NPC
have an important ‘‘bystander’’ anti-inflammatory effect on the
spleen-macrophage system [9]. Moreover in vitro NPC directly
inhibit T-cell activation and proliferation [3,10,11]. These
evidences support the concept that the ‘‘therapeutic plasticity’’
[1] and in particular the immunomodulatory activity is a true
functional signature of NPC. Nonetheless, the recent demon-
stration that other sources of somatic stem cells (i.e. mesenchy-
mal, haematopoietic), with very low capabilities of neural (trans)
differentiation, may show equally significant bystander capacities
and promote CNS repair [12–14], further proves and generalizes
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10357the relevance of somatic stem cell-dependent alternative thera-
peutic mechanisms.
Allogeneic islet transplantation serves as a source for insulin-
secreting beta cells for the maintenance of normal glucose levels
and treatment of diabetes [15]. However, limited availability of
islets, high rates of the islet graft failure and the need for life-long
non-specific immunosuppressive therapy have been major obsta-
cles in the widespread adoption of this therapeutic approach [16].
Recently, pancreatic islet transplantation was suggested as a
potential target of the ‘‘therapeutic plasticity’’ of adult stem cells.
In rat, Solari et al demonstrated that mesenchymal stem cells
promote long-term isl allograft survival in the presence of short-
term immunosuppression [17]. In mouse, we demonstrated that
tissue-derived adult mesenchymal stem cells, when co-transplanted
with a minimal pancreatic islet mass, facilitate restoration of
normoglycemia and neovascularization of the graft [18]. In
humans, combined islet and hematopoietic stem cell allotrans-
plantation was attempted to prevent graft rejection and avoid
immunosuppression-related side effects [19].
The aim of this study was to define whether NPC administered
in combination with islets prevents acute pancreatic islet allograft
rejection. Our results demonstrate that in diabetic mice receiving
allogeneic islet transplantation, the co-transplantation and co-
localization of allogeneic NPC and islets induces stable long-term
islet function that is not reversed by alloantigen re-challenge. This
condition is associated with splenic expansion of T cells with a
regulatory phenotype (i.e. CD4
+CD25
+FoxP3
+). However, stable
graft function was accompanied by constant and reproducible
development of NPC-derived cancer which was sustained by
insulin secretion. Our results demonstrate that the immune-like
functions of NPC are efficient also in non-neurological disorders
but raises serious doubts about the safety of using adult stem cells
outside the original microenvironment in combination with
insulin-producing cells.
Results
NPC co-transplantation and co-localization induce long-
term graft tolerance in fully mismatched islet transplants
Diabetic Balb/c mice were transplanted with pancreatic islets
(350 EI) and/or NPC (1000 neurospheres, GFP
+) from fully
mismatched C57BL/6 mice. The following four groups of
recipients were used: diabetic Balb/c mice receiving islets alone
(Islet-Tx, n=12); diabetic Balb/c mice receiving islets alone and
treated with rapamycin plus FK506 plus anti–IL-2Ra chain mAbs
(Edmonton-Tx, n=26); diabetic Balb/c mice receiving a mixed
islet/NPC graft under the left kidney capsule (Co-NPC-Tx;
n=10); diabetic Balb/c mice receiving the islet graft under the
left kidney capsule and the NPC graft under the right kidney
capsule (NPC-Tx; n=7) (Figure 1).
In the Islet-Tx group, the allograft was lost at a median survival
time (MST) of 1563 days and 16.7% (2/12) of allografts survived
without evidence of rejection for 100 days. The presence of
immunosuppression (Edmonton-Tx) delayed graft rejection (MST
61610 days; p=0.05 vs Islet-Tx) and 50% (13/26) of allografts
survived for 100 days (p=0.05 vs Islet-Tx; Pearson Chi-Square
test). NPC co-transplantation and co-localization with islets (Co-
NPC-Tx) prevented graft rejection (MST .100 days; p=0.007 vs
Islet-Tx) and 70% (7/10) of allografts survived for 100 days
(p=0.01 vs Islet-Tx). In contrast, when NPC were co-transplanted
but not co-localized with islets (NPC-Tx) the graft MST was 1561
days (p=0.5 vs Islet-Tx) and none of the allografts (0/7) survived
up to 100 days (p=0.2 vs Islet-Tx). To determine whether mice
that had islet graft survival .100 days had an active state of
tolerance, all transplanted mice were rechallenged in vivo with
splenocytes isolated from donor mice [20]. After the injection of
donor splenocytes, 100% of mice within the Islet-Tx group, 77%
within the Edmonton-Tx group and only 28% within the Co-
NPC-Tx group rejected their islet graft. These results indicate that
no active tolerance was achieved in the mice within the Islet-Tx
and Edmonton-Tx groups since the injection of donor-derived
antigens broke the state of immune incompetence leading to graft
rejection [20]. On the contrary, Co-NPC-Tx mice displayed a
state of active and stable long-term tolerance that was not broken
by alloantigen rechallenge. Overall, the proportion of mice
achieving long-term tolerance (i.e. accepting the primary graft
and retaining the graft after rechallenge) was 50% in the Co-NPC-
Tx group, 13% in the Edmonton-Tx group and 0% in Islet-Tx
and NPC-Tx groups (Table 1).
Islet/NPC co-transplantation and co-localization induce
NPC transformation and tumor formation
All mice that were still alive 140 days after allo-transplant (11/
12, 6/7 and 10/10 for Islet-Tx, NPC-Tx and Co-NPC-Tx
respectively) were sacrificed. Concordantly with the presence of
hyperglycaemia, all mice within the Islet-Tx group (11/11), the
NPC-Tx group (6/6), and the Co-NPC-Tx group (3/10) that had
lost islet function during the first 100 day, had neither macroscopic
nor microscopic residual grafted tissue (islet and/or NPC) under
their kidney capsules. No GFP+ cells were present in the draining
lymph nodes or in the spleens. On the other hand, all seven mice
within the Co-NPC-Tx group that did not reject the graft 100 days
after transplantation had tumors at the site of islet/NPC
implantation (Table S1 and Figure S1). All tumors stained positive
for GFP, showing that they derived from the grafted NPCs. In the
five mice that maintained euglycaemia after alloantigen rechal-
lenge, histological analysis demonstrated insulin positive islets
embedded within the tumor and localized preferentially close to
the kidney (Figure 2). The frequency of leucocytes infiltrating the
tumors and more specifically the islets, was very low. However,
when present, infiltrating cells were confined to the periphery of
the islets whereas intra-islet infiltrating mononuclear cells were not
observed (Figure 2).
Islet/NPC co-transplantation and co-localization
associates with a splenic expansion of FoxP3
+ and
CD4
+CD25
+FoxP3
+ T regulatory cells
The frequency of the major hematopoietic populations was
analyzed in spleens of mice within the Islet-Tx, NPC-Tx, and Co-
NPC-Tx groups and of untreated age and gender matched Balb/c
mice (Table 2). Transplantation changed per se the splenocyte
composition leading to decreased CD8
+ T cells, influencing the
naı ¨ve/effector T-cell ratio (Table 2, CD45RBhigh expression on
CD4
+ and CD8
+ T cells), and favoring the expression of MHCII
and costimulatory molecules on CD19
+B220
+ B cells and CD11b
+
myeloid cells. Interestingly, among the transplanted mice, those
within the Co-NPC-Tx group showed a significant reduction of
the percentage of total CD4
+ T cells with a concomitant significant
expansion of the percentage of FoxP3
+ and CD4
+CD25
+FoxP3
+
regulatory T cells. Moreover, a further increase of MHCII and
CD86 expression was evident in CD19
+B220
+ B cells and CD11b
+
myeloid cells.
Islets and insulin are required for NPC transformation and
tumor formation
To evaluate whether the co-localization with islets is the ‘‘sine
qua non’’ condition for promoting NPC transformation, 8 diabetic
NPC and Pancreatic Islets
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(350EI) and syngeneic GFP
+ NPC (1,000 neurospheres) under the
left kidney capsule and with syngeneic GFP
+ NPC alone (1,000
neurospheres) under the right kidney capsule (see Table S1). All
mice normalized glycaemia. Islet function was maintained for 100
days after transplant with the exception of two mice: one died at
day 85 and one lost islet function at day 78. At day 100, a tumor
was present only in the left kidney in all seven surviving mice.
Subsequently, to test whether tumor development was sustained
by insulin secretion we substituted islets with an insulin releasing
pellet. Three diabetic C57BL/6 mice were transplanted with
syngeneic NPC (1,000 neurospheres) and sustained release insulin
Table 1. Percentage of mice in which stable long-term graft survival was achieved after different treatments.
Transplant group Kidney capsule n 100 days after Tx After rechallenge Overall
Left Right GS MST GS MST GS MST
Islet-Tx Islet Sham 12 2/12 1563 0/2 7 0/12 1466
Edmonton-Tx Islet Sham 26 13/26
* 61610
* 3/13 2164 3/26 61653
1
Co-NPC-Tx Islet/NPC Sham 10 7/10
1 .100
1 5/7 .40 5/10
# 112
#
NPC-Tx Islet NPC 7 0/7 1561- 0 / 7 1 5 61
Graft survival (GS): data are n. Median survival time (MST): data are days 6standard error.
*P#0.05 vs Ctrl;
1P#0.01 vs Ctrl;
#P#0.005 vs Islet Tx.
doi:10.1371/journal.pone.0010357.t001
Figure 1. NPC/islet cotransplantation and colocalization prevents allograft rejection. Diabetic Balb/c mice were transplanted under the
kidney capsule with 350 EI purified from C57BL/6 mice. Mice were not treated (Islet-Tx, n=12) or treated with rapamycin plus FK506 plus anti–IL-2Ra
mAb (Edmonton-Tx, n=26), or co-transplanted with NPC (1,000 neurospheres) under the same kidney of the islets (Co-NPC-Tx, n=10) or under the
controlateral one (NPC-Tx, n=7). Gray area: all diabetic Balb/c mice that were transplanted 100 days before with C57BL/6 islets were challenged with
donor-derived splenocytes. Left Panel: Kaplan-Meier Analysis for the graft survival between the four groups of recipients. Hundred days after
transplantation there was a significant difference between Edmonton-Tx and Islet-Tx or between Co-NPC-Tx and Islet-Tx. In contrast, there was no
statistical significant difference between NPC-Tx and Islet-Tx. In all cases, the graft survival was monitored by glycemia levels. A graft was considered
rejected when glycemia was .300 mg/dl for two consecutive measurement. *P,0.05 and **P,0.01 vs. Islet-Tx, Log Rank-Kaplan-Meier analysis.
Right Panel: not fasting blood glucose profile of Islet-Tx and Co-NPC-Tx after receiving islets. Data are expressed as mean (line) and 61 standard error
(area).
a Statistical analysis was performed by tests of repeated measures ANOVA considering two intervals: from 0 to 100 days (before donor-derived
splenocytes boost) and from day 100 to day 140 (after donor-derived splenocytes boost). * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0010357.g001
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under the left kidney capsule and with syngeneic NPC alone (1,000
neurospheres) under the right kidney capsule. After 140 days all
animals (3/3) showed tumor formation in the left kidney (Figure
S2). In the right kidney, at the level of NPCs implantation, fluid-
filled microcysts were recognizable. These cysts were lined by a
multiple layer of phenotypically non transformed neuroepithelial
cells (Figure S2). All together these data demonstrate that insulin is
a determinant of NPC transformation in vivo.
NPC-derived tumors are neuroblastoma-like neoplasms
with malignant features
The median volume of developed tumors was 3.1 cm
3 (range
0.1–6.4). In 2 of 7 mice (28%) peritoneal and liver GFP+
metastases were present and associated with ascites. Tumors had a
variable morphological appearance by histological evaluation
(Figure 3). They generally appeared non-encapsulated, densely
cellular with variable areas of necrosis (5 to 30%), well
circumscribed although focally infiltrating adjacent tissues (Figure
S3). Evaluation of Ki-67 staining showed an impressive high
proliferation index in all tumors (positive cell .80%) (Figure S3).
Features of differentiated and undifferentiated neuroblastoma
were easily recognizable in large tumor areas (,60%) with
neuroepithelial cells (small cells S100
+ with hyperchromatic nuclei
and scant cytoplasm) sometimes arranged in the classic pseudorosette
pattern (Figure 3). In addition to the neuroblastoma areas, spindle
cell sarcomatoid components mainly as densely cellular areas and
less frequently immersed in a myxoid stroma, were present. The
spindle cell component stained positively, at least focally, for
smooth muscle actin (data not shown). Moreover, within the
tumors, it was possible to recognize foci of angiomatoid,
epithelioid, condroid and osteoid differentiation (Figure 3).
Primary adherent cell cultures were established from 4 of 14
primary tumors (#1, #3, #8, and #16) and from 1 of 2 ascites
(#3a). All these NPC-derived tumor cell cultures (NPC-DTCC)
generated ‘‘secondary’’ tumors in vivo when injected into syngeneic
recipients. Two additional NPC-DTCC were established from
these ‘‘secondary’’ tumors (#1bis, #3bis). All the cells in culture
were and remained positive for GFP, demonstrating their original
derivation from NPC (Figure S4). All NPC-TDCC maintained
stable growth capacity in vitro (Figure S5 and Table 3) and
continuously proliferated in serum-supplemented medium without
any addition of growth factors for up to 32 passages (correspond-
ing to 280 days). Cell cycle and Q-banding karyotypic analysis at
early passages (passage 2–8) showed that aneuploidy and
chromosomal aberrations frequently occur in NPC-TDCC
(Figure 4). Less than 10% of total metaphases analyzed displayed
euploidia and cell cycle analysis showed a significant increase of
the hyper G2 fraction in comparison to pre-transplant NPC
(Table 3). Moreover, we detected the presence of atypical
metacentric chromosomes, probably as a result of chromosomal
end-to-end fusions of Robertsonian type (Figure 4). The average
cell number yielded per passage during in vitro culture ranged from
3.5610
6 at p1–p5 to 7.5610
6 at p6-p10 to 10
7 at later passages
(p11–16), suggesting that culturing resulted in an increased
proliferation rate (Figure S5). The quantitative analysis of the
frequency of CNS lineages in the NPC-DTCC (Figure 5) showed
that 72620% of cell stained for oligodendroglial marker (NG2
Figure 2. Co-NPC-Tx: transplant histology. Histological appearance (left 4x, insert 20x) of allogeneic islet/NPC co-transplantation in a
representative Balb/c mouse 140 days after transplantation. Islets (Is) appeared embedded in tumor tissues, localized preferentially close to kidney
tissue and stained strongly for insulin (brown). The frequency of leucocytes infiltrating the tumors and more specifically the islets, was very low (Insert
B). However, when present, infiltrating cells were confined to the periphery of the islets whereas intra-islet infiltrating mononuclear cells were not
observed (insert A, white arrow).
doi:10.1371/journal.pone.0010357.g002
NPC and Pancreatic Islets
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neuronal marker (Neuronal class III beta tubulin) and 9664%
of cells stained for astroglial marker (Glial fibrillary Acidic Protein).
Discussion
Athough pioneer in vivo studies with NPC focused mainly on
their ability to promote structural and functional repair of
damaged brain tissues owing to their ‘stem-cell’ properties, the
data available on the immunomodulatory properties of NPC
support their possible use as a modulator for immune-mediated
process.
We tested the possibility to use NPC as cell therapy for tolerance
induction in tissue transplantation outside the central nervous
system. The immunomodulatory activity of NPCs has been
previously described exclusively in experimental models of
neurological disease (i.e. experimental autoimmune encephalomy-
elitis, intracerebral haemorrhage) [3–7,9–11] and after systemic
injection due to their interaction with immune cells in secondary
lymphoid organs [8].
We demonstrate that a cell therapy approach that combines
NPCs with islet transplant prevents acute islet allograft rejection,
enriches CD4
+CD25
+FoxP3
+ regulatory T cells in the spleen and
induces active tolerance. On the other hand, this condition
appears strictly associated with the development of NPC-derived
cancers mainly sustained by insulin secretion.
These results introduce a new concept in the field of stem cell-
based therapy and provide a new experimental model to study the
stem-cell oncogenesis associated with immune escape. NPCs were
previously described to display a strikingly stable profile with
regard to self-renewal, expansion, differentiation, growth factor
dependence, karyotype and molecular profiling. Foroni et al.
reported that when forced to grow in vitro for over 100 passages,
NPCs do not undergo transformation and never give rise to
tumors in vivo, even when immortalized through delivery of Myc
and Ras oncogenes [21]. A single previous report has proposed
that the extensive culturing of NPCs [22–27] might select for
aggressive cell clones but only after very long-term culture [27].
More generally, many studies strongly support the notion that
spontaneous transformation of adult stem cells can take place
exclusively after long-term culture in vitro [22–27]. Here, we
demonstrate that adult multipotent neural stem/precursor cells
can generate cancer in vivo even when used after short-term culture
in vitro. In fact, we avoided using NPCs from neurospheres beyond
15 passages and NPCs appeared euploid with normal karyotype at
time of injection. Despite this, 70% and 100% of mice
transplanted with allogeneic or singeneic NPCs respectively
unequivocally developed cancer. The malignant nature of these
tumors was demonstrated by the histological morphology, by the
presence of metastatic behaviour in vivo and by the expression of all
the features of malignant cancer cells in vitro (i.e. capacity to
extensive proliferation, unlimited self-renewal ability, loss of
growth-factor dependence, clonogenicity, karyotype changes with
chromosomal aberrations, aneuploidia, tumorigenic activity and
multipotency).
The localization of NPCs with islets in the same microenviron-
ment appears the ‘‘conditio sine qua non’’ for cancer development,
since we did not observe tumors in NPCs transplanted alone both
in allogeneic and syngeneic settings. This evidence introduces the
concept that ‘‘safety’’ of stem cell therapy in terms of cancer
generation is not only an intrinsic property of stem cells, but is also
strictly dependent on cross talk with the microenvironment. In our
Table 2. Phenotype of spleen derived cells.
Untreated Balb/c Mice N=5 Islet-Tx N=11 NPC-Tx N=6 Co-NPC-Tx N=10 P
CD4
+ 31622 4 632 7 661 5 68
a,b,c ,0.001
- CD25
+ 5611 8 67
a 10662 6 68
a,c ,0.001
- FoxP3
+ 15+21 8 641 6 632 3 62
a,b,c ,0.001
- FoxP3
+/CD25
+ 9+11 1 657 631 6 63
a,b,c ,0.001
- CD62L
+ 72636 0 69N t 5 8 616 Ns
- CD25
+/CD62L
+ 4619 64
a Nt 1062
a 0.003
- CD45Rb high
+ 80625 6 67
a 5765
a 5369
a ,0.001
CD8
+ 11688 63
a 662
a 662
a 0.001
- CD45Rb high
+ 93617 5 66
a 7166
a 63620
a 0.002
CD14
+ 160.2 4631 614 63N s
Gr1
+ 160.2 3645 673 62N s
Gr1
low/B220
+ 0.260.5 462
a,c 2614 62
a,c ,0.001
CD19
+/B220
+ 41635 3 674 2 625 0 620 Ns
- I-Ab
+ 1.560.3 1267
a 360.8 22610
a,b,c ,0.001
- CD86
+ 0.560.5 21614
a,c 7633 7 67
a,b,c ,0.001
CD11b
+ 1.560.1 4.262.3 7.862.9 4.862.1
a,b,c ,0.001
- I-Ab
+ 1.1460.6 67637
a 33625 8968
a,c ,0.001
- CD80
+ 9627 5 631
a 54631
a 9464
a,c ,0.001
- CD86
+ 9627 3 632
a 46630 89614
a,c ,0.001
Data are expressed as percentage 6SD. Statistical analysis was performed by one-way ANOVA with Bonferroni post-hoc test:
a=p ,0.05 vs Balb/c Mice;
b=p ,0.05 vs Islet-Tx;
c=p ,0.05 vs NPC-Tx;
d =p ,0.05 vs Co-NPC-Tx. Ns=not statistically significant; Nt= not tested.
doi:10.1371/journal.pone.0010357.t002
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transformation of NPCs. Identification of the mechanisms by
which insulin induces the NPC transformation was beyond the
scope of this study and will be the matter of future work. However,
we can speculate that insulin may modulate cancer development
through both the insulin receptor and insulin like growth factor-1
receptor (IGF-1R). Insulin receptor activation by insulin triggers
intracellular signalling cascades in both the extracellular-signal-
regulated kinase (ERK) and phosphotidylinsositol-3 kinase (PI-3K)
pathways, and thus, insulin signalling has the ‘‘machinery’’ to be
mitogenic and anti-apoptotic [28]. Conventionally, however, it is
thought that insulin is mitogenic only at supraphysiological levels
and its main proliferative effects are probably mediated through
the IGF-I-1R. Of note is the fact that both insulin receptor and
IGF-1R were repeatedly shown to be associated with brain tumour
development, proliferation and response to therapy in humans.
The presence of an active IGF system has been established in
glioblastoma [29], neuroblastomas [30], astrocytomas and menin-
giomas [31]. Similarly atypical teratoid/rhabdoid tumours of the
CNS over-express the insulin receptor [32].
The localization of NPCs with islets in the same microenviron-
ment appears the ‘‘conditio sine qua non’’ for preventing rejection,
as demonstrated by the fact that mice transplanted with islets
under the left kidney capsule and with NPCs under the right
kidney capsule did not develop tolerance. Since graft survival was
always associated with cancer development, the competence in
inducing tolerance appears associated with oncogenic transforma-
tion rather than to an intrinsic property of NPCs. The mechanisms
by which NPC oncogenic transformation protects islet from
alloimmune attack is likely to be similar to those observed during
drug-mediated tolerance induction. The histological appearance of
the transplant (very low cellular infiltration and, when present,
confined to the periphery of the islets) is consistent with that
described previously during drug-mediated tolerance via expan-
sion of regulatory T cells [20]. Over the last years a number of
reports have described elevated numbers of in situ mechanisms
able to block the immune reaction in tumor microenvironment,
including the presence of regulatory T cells [33–35]. In agreement
with this hypothesis, in our model, tolerance was associated with a
significant reduction of total CD4
+ T cells and with a concomitant
expansion of CD4
+CD25
+FoxP3
+ regulatory T cells in the spleen.
Of note, patients with malignant tumors of central nervous system
(i.e. gliomas) are characterized by dramatic reductions in CD4
+ T
cell number and a disproportionate presence of immunosuppres-
Figure 3. Co-NPC-Tx: tumor histology. Variable morphological appearances within the haematoxylin and eosin stained tumours: (A) neural and
spindle mixoid components (4x); (B) neural component (10x); (C) spindle mixoid components(10x); (D) angiomatoid component (10x); (E)
differentiated and undifferentiated neural components (20x); (F) neural and spindle component (20x); (G) osteoid and epitheliod components (20x);
(H) condroid component (40x); (I) spindle component (40x). Kd=kidney.
doi:10.1371/journal.pone.0010357.g003
NPC and Pancreatic Islets
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bearing NPC-derived tumors. However, we cannot exclude that
other mechanisms play a relevant role in preserving tumor
embedded islets, including the release of local immunosuppressive
factors, the inability of leukocytes to infiltrate neoplastic tissue and
the presence of a generalized immune-compromised state due to
the large tumor mass. At this time we do not know whether
transplantation of tumor cells from any other cellular origin can
produce results similar to those obtained with NPCs. It should also
be considered that if there are identifiable specific immunomod-
ulatory factors produced by the transformed NPCs that protects
transplanted islets, this could have therapeutic implication, even if
the NPCs cause tumors. Of note, the release of major
developmental stem cell regulators, including the morphogens
bone morphogenetic protein (BMP)-4 and sonic hedgehog (Shh),
the extracellular matrix protein tenascin C, and the BMP
antagonist Noggin have been reported to be responsible for
immune regulatory activity of ‘‘normal’’ NPCs [8].
More generally, and beyond our original intention, transplan-
tation of NPCs with islets offers an experimental model to study
the oncogenesis associated with immune escape. In fact, NPC-
derived cancer grows in fully mismatched allogenic recipients.
Moreover cancer development is relatively fast, frequent and
reproducible offering the possibility to study both the oncogenetic
process in vivo at different stages (starting from non neoplastic
NPC to malignant NPC-DTCC) and the associated mechanisms
of immune escape.
In conclusion, our results demonstrated that in diabetic mice
receiving allogeneic islet transplantation the concomitant admin-
istration of NPCs induce stable long-term islet function in the
absence of immunosuppression and that this was not reversible by
alloantigen re-challenge. This condition was associated with
splenic expansion of CD4
+/CD25
+/FoxP3
+ cell. Unfortunately,
we also found constant and reproducible development of NPC
derived cancer mainly sustained by the insulin secretion. Our
result raises serious doubts about the safety of using adult stem cells
outside the original microenvironment.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant international (Directive 86/
609/EEC and the recommendation 2007/526/EC from Europe-
an community), national (Legislative Decree 116/92 and law n.
413/1993) and according to protocol approved by the Animal
Care and Use Committee of the Fondazione San Raffaele del
Monte Tabor (IACUC #280) and communicated to the Ministry
of Health and local authorities according to the Italian law. As a
general rule we applied all available methods to replace, reduce and
refine animal use (Three Rs) in our experimental plan. All
experiments were terminated 140 days after islet Tx or when
significant sign of animal suffering became apparent. All interven-
tions were performed under general anaesthesia if suffering had to
be expected. All animal experiments were performed in our central
animal facility by trained and experienced personnel. Accreditation
from the local authorities has been obtained for all personnel
involved in animal experiments.
Islets isolation and culture
Pancreatic islets were isolated from C57BL/6 mice (nine weeks
old, 20–22 g; Charles River, Calco, Italy) by a collagenase digestion
method, as described [37]. Briefly, 2 ml of cold Hank’s buffer/
collagenase type V solution (1 mg/ml; Sigma, St Louis, MS, USA)
was infused into the pancreatic duct insitu, and the removed pancreas
was digested at 37uC for 15 min. Islets were purified on a
discontinuous Ficoll gradient (Sigma). The islets (250 islet/ml) were
cultured free-floating (37uC, 5% CO2)i nm e d i u mR P M I1 6 4 0( B i o -
Whittaker, Walkersville, MD, USA) supplemented with L-glutamine
(Sigma), penicillin-streptomycin (1000 U/ml-10 mg/ml; Sigma) and
Table 3. NPC-derived tumor cell cultures (NPC-DTCC) characteristics.
Pre Tx NPC #1 #3 #3a #8 #16 #1bis #3bis
Passage number #p 1 5 p 8 p 3p 4 p 2p 4p 5p 7
Cell cycle Analysis
- subG1 14 37 58 16 14 22 31 8
- G1 45 49 6 15 46 42 21 54
- S 71- 2 5 4 3 3
- G 2 3 21 11 1 2 7 1 3 3 0 2 7 2 0
- HyperG2 3 3 24 30 11 3 18 16
- G2/G1 0.71 0.22 1.7 1.9 0.3 0.7 1.3 0.4
Karyotype
- chromosome
1 40 (40/42) 40 (38/43) 39 (34/79) 66 (37/78) 43 (39/50) 42 (40/45) 59 (55/90) 53 (33/58)
- euploidia
# 90% (18/20) 40% (8/20) 0% (0/9) 0% (0/19) 0% (0/12) 5% (1/20) 0% (0/15) 0% (0/15)
Doubling time (h) 72 38 48 45 94 85 51 48
Clonogenicity* 16.1 8.3 2.5 15.7 54.2 92 10.7 Nt
In vivo tumorigenicity:
-Under skin (1610
6 cells) 0/8 3/3 3/3 3/3 3/3 3/3 3/3 3/3
-Kidney capsule (1610
6 cells) 0/8 3/3 3/3 3/3 3/3 3/3 3/3 3/3
1data are expressed as number median (min/max).
#data are expressed as % of methaphases with 40 Chr and (n).
*expressed as number of cell for well to obtain clone development in 50% of wells (see Material and method); Nt= not tested.
doi:10.1371/journal.pone.0010357.t003
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for 20–24 h before the transplant. Islet purity was .90%.
NPC derivation and cultures
Adult neurospheres were generated from the SVZ of four-to-
eight week-old C57Bl/6, as described [8]. Mice were anesthetized
by intraperitoneal injection of pentobarbital (120 mg/kg) and killed
by cervical dislocation. The brains were removed and placed in
artificial cerebrospinal fluid (aCSF) (124 mM NaCl, 5 mM KCl,
1.3 mM MgCl2, 0.1 mM CaCl2, 26 mM NaHCO3, and 10 mM
D-glucose, pH 7.3) aerated with 95% O2/5% CO2 at room
temperature. The SVZ neural tissue – excluding the subependyma
– was isolated after coronal sectioning and cut into 1 mm
3 pieces.
Pieces were transferred into 30 ml of aCSF containing 1.3 mg/ml
trypsin, 0.67 mg/ml hyaluronidase, and 0.2 mg/ml kynurenic acid
(all from Sigma) and incubated, under continuous oxygenation and
stirring, for 90 min at 32–34uC. Tissue sections were then rinsed in
aCSF for 10 min, transferred to DMEM/F12 (Life Technologies,
Rockville,MD)mediumcontaining0.7 mg/ml ovomucoid (Sigma),
and carefully triturated with a fire-polished Pasteur pipette. Cells
were collected by centrifugation and re-suspended in GF-free,
chemically defined DMEM/F12 medium containing 2 mM L-
glutamine, 0.6% glucose, 9.6 mg/ml putrescine, 6.3 ng/ml pro-
gesterone, 5.2 ng/ml sodium selenite, 0.025 mg/ml insulin,
0.1 mg/ml transferrin, and 2 mg/ml heparin (Sigma). Cells were
then cultured in NeuroCultH Proliferation Kit (Stem Cell
Technologies, Vancouver BC, Canada). The number of primary
spheres was counted after 7–12 days in vitro (DIV). For cell
amplification, 8000 cells/cm
2 were plated at each sub-culturing
passage in untreated tissue culture flasks. After 3–4 days (time
estimatedto obtain the doubling of cell number), neurospheres were
harvested, mechanically dissociated, counted and re-plated under
the same culture conditions. NPCs at passage number #15 were
used in all experiments. Cells were labelled in vitro using a lentiviral
vector containing the enhanced green fluorescent protein (GFP).
Islets and NPC transplantation
Male Balb/c mice (nine week old, 20–22 g; from Charles River)
were used as recipients. Mice were made diabetic (non-fasting
blood glucose levels between 400 and 600 mg/dl) with intravenous
STZ injection (175 to 200 mg/kg; Sigma) one week before
transplantation. The recipient mice were anesthetized with
isoflurane (Forane 1–2%; Abbott Laboratories, Toronto, Canada).
Islets were transplanted as previously described [37]. Briefly, after
Figure 4. Cell-cycle and karyotype assessments of NPC-derived tumor cell cultures (NPC-DTCC). Cell-cycle profile, examples of
metaphase and chromosome number distribution from karyotype analysis in pre Tx NPC (p15) and NPC-DTCC (#1, p8; #3, p3; #3a, p4; #8, p2; #16,
p4, #1bis, p5; #3bis, p7). Sub G1, G1, S, G2 and hyper G2 fractions were calculated as reported by the markers in pre Tx NPC panel. Yellow arrows in
metaphase picture indicate abnormal metacentric chromosomes. Chromosome number distribution: X axis represents the number of chromosome
counted during the metaphase, Y axis represent the number of metaphase. A minimum of 9, a maximum of 20 metaphases were analyzed for each
cell culture.
doi:10.1371/journal.pone.0010357.g004
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inserted through a small incision into the lower pole of the kidney
and pushed to the upper pole, whereupon the islets were gently
pushed beneath the kidney capsule, the cannula was removed, and
the incision was cauterized. The following four groups of recipients
were used: group 1 received a pure islet graft (350 equivalent islets
[EI]; n=12); group 2 received a mixed islet/NPC graft (1610
3
NPCs as neurospheres plus 350 equivalent islets under the capsule
of the left kidney; n=10); group 3 received islets and NPC graft
(1610
3 NPCs as neurospheres under the capsule of right kidney,
350 equivalent islets under the capsule of the left kidney; n=7);
group 4 received a pure islet graft in the presence of
immunosuppression (350 equivalent islets; n=26). As immuno-
suppression we used the Edmonton protocol consisting of
rapamycin plus FK506 plus anti–IL-2Ra chain mAbs [38]. The
treatment of the transplanted Balb/c mice began the day after
transplant. Rapamycin (Rapamune; Wyeth-Ayerst, Pearl River,
NY) was diluted in peanut oil (Sigma) and administered once daily
for 30 consecutive days at a dose of 1 mg/kg by gavage. FK506
(Prograf; Fujisawa) was diluted in saline solution and administered
once daily for 30 consecutive days at 0.3 mg/kg, i.p. Anti–mouse
IL-2Ra chain mAb (clone 7D4; BD Biosciences, Mountain View,
CA) was diluted in saline solution and administered intraperito-
neally at time 0 and 4 days after islet transplantation to reach a
dose of 1 mg/mouse. Blood glucose levels were measured using a
Glucometer Elite (Bayer Canada, Toronto, Ontario, Canada) at
15, 30 and 60 minutes after the end of surgical procedure, daily for
the first week and then every second day post-transplantation. The
animals had free access to tap water and pelleted food throughout
the course of the study. The local animal ethics committee
approved all experiments. Surgical death was defined as death
within the first 7 days after transplantation. Primary graft non
function was defined as the inability to reach non-fasting blood
glucose levels under 250 mg/dl for two consecutive measurement
after islet transplantation, and rejection was defined as two
successive measurements .300 mg/dl in mice where primary
function was achieved. The Balb/c mice that did not reject the
islet allograft 100 days after transplantation were boosted in vivo
with allogeneic splenocytes [20]. A total of 30610
6 splenocytes
isolated from C57BL/6 mice were injected intraperitoneally.
Blood glucose levels were monitored daily thereafter for 40 days,
then mice were killed, transplant and spleen were collected.
Sustained Release Insulin Implants and NPC
transplantation
To specifically test the role of insulin on NPC, in some
experiments we substituted islets with an insulin releasing pellet.
Figure 5. Multipotency of NPC-derived tumor cell cultures (NPC-DTCC). Upper Panel: Analysis of NPC-DTCC multipotency at passages 24 by
immunofluorescence for neuronal (Neuronal class III beta tubulin), astroglial (Glial fibrillary Acidic Protein), and oligodendroglial (NG2 Chondroitin
Sulfate Proteoglycan) markers (line #1, representative of all NPC-DTCC). All the cells in culture maintained the positivity for GFP, demonstrating their
NPC origin Lower Panel: quantitative analysis of the frequency of CNS lineages in the NPC-DTCC at passages 16. Neuronal, glial, oligodendroglial
markers were detected by immunofluorescence. Values are expressed as percentage of immunoreactive cells over the total cell number. A minimum
of 100 and a maximum of 1500 cells were evaluated for each marker.
doi:10.1371/journal.pone.0010357.g005
NPC and Pancreatic Islets
PLoS ONE | www.plosone.org 9 April 2010 | Volume 5 | Issue 4 | e10357After exposure of the left kidney, P-50 tubing containing NPC was
inserted through a small incision into the lower pole of the kidney
and pushed to the upper pole, whereupon the cells were gently
pushed beneath the kidney capsule, the cannula was removed.
Then we pushed a 263 mm insulin release pellet (LinBit for mice,
Linshin Canada. Inc. Ontario, Canada) through the capsule
orifice just created from the cannula and the incision was
cauterized. Insulin release rate from the pellet is ,0.1 U/24 hr/
implant for .30 days. The implant dose has enough insulin to last
for .40 days at the specified release rate The remnants of the
insulin-depleted implants are totally absorbed in the next weeks,
and removal is not necessary.
Preparation and analysis of spleen mononuclear cells
Cell culture medium was prepared with RPMI 1640 (Bio-
Whittaker, Walkersville, MD, USA) supplemented with 1000 U/ml
penicillin-streptomycin (Sigma) and 10% (vol/vol) FCS (fetal calf
serum, HyClone, Celbio, Logan, UT, USA). Spleen from
transplanted and non-transplanted control mice were harvested
and processed within 2 h mouse sacrifice. Tissues were first
homogenized in sterile 0,4 mm cell strainers to remove large debris.
To lyseserythrocytes,the cell suspensionwasresuspended in1 mlof
sterile water and immediately washed in cell culture medium. Cell
staining and flow cytometry analysis staining buffer was prepared
with PBS (Phosphate buffered saline, without Ca2+ and Mg2+,
EuroClone Ltd., Torquay, UK) supplemented with 2,5% (vol/vol)
FCS and 0,01% (vol/vol) sodium azide. All monoclonal antibodies
specific for surface antigen were directly conjugated and purchased
from BD pharmingen (San Jose, California). No tandem-dye-
conjugated monoclonal antibodies were used. Intracellular staining
for FoxP3 was performed with FITC-conjugated anti-mouse FoxP3
(clone FJK-16s) and FoxP3-staining kit (both from eBioscience San
Diego, California). For each staining a total of 3610
5 splenocytes
were incubated 30 min at 4uC with the respective monoclonal
antibodies properly diluted in staining buffer. Cells were than
washed and resuspended in 200 ml of staining buffer and acquired
within 24 hours. Intracellular staining for FoxP3 was performed
with the kit-provided buffers and following the suggested protocol.
All samples were acquired on a CyAn ADP (Beckman Coulter,
Brea, California, USA) or on a FacsCanto II (BD Biosciences)
instrument. Flow cytometry data analysis was performed with
Summit ver 4.3 (Beckman Coulter, Brea, California, USA) or
Fcsexpress ver 3.0 (De Novo Software).
Characterization of harvested grafts
For morphological investigation the recipients were sacrificed
140 days after transplantation: the kidney was removed and fixed
in 10% buffered formalin and processed for histology. Histologic
sections were stained with hematoxylin and eosin (H&E) or for
insulin with the use of an anti-insulin guinea pig primary
polyclonal antibody (Dako, Carpinteria, CA, USA). The strepta-
vidin-biotin method (LSAB-2 Kit; Dako) or AffiniPure anti–guinea
pig tetramethylrhodamine-5 (and 6)-isothiocyanate (TRITC)
secondary antibodies (Jackson ImmunoResearch Laboratories)
were used for detection.
NPC-derived tumor cell cultures (NPC-DTCC), culture
propagation, population analysis, and cloning
Seven primary cell cultures were established from NPC-derived
tumor. Cells were plated at a density of 8,000/cm
2 in RPMI 1640
(Bio-Whittaker) supplemented with L-glutamine (Sigma), penicil-
lin-streptomycin (1000 U/ml-10 mg/ml; Sigma) and 10% (vol/
vol) fetal calf serum (HyClone). For growth curves, 200,000 cells
were replated in a 25-cm
2 flask after each subculturing passage.
Population and serial clonal analyses were done as described
previously [21]. Cell cycle analysis was performed by propidium
iodide (Sigma) staining of permeabilized cells. Clonal efficiency
was assessed using a limiting dilution assay. Briefly, 0.1 to 50 cells
per round- bottomed well (96-well plate) were incubated in 100 ml
RPMI 1640 (Bio-Whittaker) containing 10% FCS. Twelve wells
were seeded per cell concentration. After 14 days of culture,
positive wells were scored using an inverted microscope. Clonal
efficiency was quantified as the cell concentration able to obtain
clones development in 50% of wells. Tumorigenicity of NPC-
TDCC was determined by injecting 1610
6 cells at passages 5
either s.c. or under the kidney capsule of 12-week-old syngeneic
C57BL/6 mice. Chromosome analysis was done as previously
described [21]. Briefly, cells were treated with medium containing
10 mg/mL Colcemid (Irvine Scientific, Santa Ana, CA) for 1 to
2 hours and resuspended in hypotonic 1% sodium citrate at room
temperature for 30 minutes. The cells were then washed in
methanol-acetic acid (3:1, v/v) fixative solution for 30 minutes and
spread onto clean dry slides. Q-banding staining was then
performed, and 9 to 20 metaphases were analyzed for each
sample. Immunofluorescence for neural antigens was done as
previously described [39]. Mouse monoclonal antibody against
Neuronal Class III b-Tubulin (Covance, California), polyclonal
rabbit anti-Glial Fibrillary Acid Protein (Dako, Carpinteria, CA,
USA) and polyclonal rabbit anti-NG2 Chondroitin Sulfate
Proteoglycan (Chemicon, USA) were used for the immunostain-
ing. AffiniPure anti–mouse or anti-rabbit tetramethylrhodamine-5
(and 6)-isothiocyanate (TRITC) secondary antibodies (Jackson
ImmunoResearch Laboratories) were used for detection. Sections
were mounted in VECTASHIELDH Mounting Medium with
DAPI (Vector Lab, CA). Quantification of positive cells was
performed with IN Cell Workstation 3.5 software.
Statistical analysis
Significance of difference between groups was tested using the
Mann-Whitney U test, Kruskal Wallis test, Pearson chi-square
tests and One Way ANOVA test. Survival differences were tested
using the log rank statistic. For all analyses, a two-tailed P value of
0.05 was considered significant. Statistical analyses were per-
formed using the Statistical Package for Social Science (SPSS 13.0;
SPSS, Chicago, IL).
Supporting Information
Figure S1 NPC/islet co-transplantation and co-localization
induces tumor formation. Diabetic Balb/c mice were transplant-
ed under the kidney capsule with 350 equivalent islets purified
from C57BL/6 mice. Islets were transplanted alone under the left
kidney capsule (Islet-Tx) or co-transplanted with GFP+NPC
(1,000 neurospheres) alternatively in controlateral right kidney
(NPC-Tx) or co-localized in the left kidney (Co-NPC-Tx). The
mice surviving until day 140 were sacrificed. A laparotomy to
evaluate the graft-bearing kidney was performed. No residual
macroscopic or microscopic grafted tissue (islet or GFP+NPC)
were recognized at the level of the kidney capsules in Islet-Tx and
NPC-Tx (respectively Panel A and B). On the other hand, in 7/
10 of the Co-NPC-Tx tumor mass substituted the kidney
parenchyma (Panel C. Upper: case #1; lower: case #3; see
table 2). After tissue perfusion and washing tumor were analyzed
for GFP expression using inverted fluorescent microscopy. The
tumoral tissue showed a strong positivity for GFP. Black arrow:
left kidney.
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PDF)
Figure S2 NPC/insulin releasing pellet co-transplantation and
co-localization induces tumor formation. Three diabetic C57BL/6
mice were transplanted with syngeneic NPC (1,000 neurospheres)
and sustained release insulin implants (release rate: ,0.1 U/
24 hr/implant for .30 days) under the left kidney capsule and
with syngeneic NPC alone (1,000 neurospheres) under the right
kidney capsule. Panel A: not fasting blood glucose profile after
receiving NPC/insulin releasing pellet co-transplantation. Data
are expressed as mean (line) and 61 standard deviation (area).
Panel B: morphological appearances of the haematoxylin and
eosin stained kidneys. Histological appearance (1x, insert 20x) of
NPC/insulin releasing pellet (upper) and NPC alone (lower) in a
representative C57BL/6 mouse 140 days after transplantation.
Found at: doi:10.1371/journal.pone.0010357.s002 (0.82 MB
PDF)
Figure S3 Malignant features of NPC-derived tumor. (A) NPC-
derived tumor infiltrating adjacent kidney (H&E; 10x); (B) Ki-67
staining on NPC- derived tumors (4x).
Found at: doi:10.1371/journal.pone.0010357.s003 (0.81 MB
PDF)
Figure S4 NPC-derived tumor cell cultures (NPC-DTCC).
NPC-DTCC derived from tumors of mice co-transplanted with
islet and GFP+ NPC. All the cell in culture were and maintained
the positivity for GFP, demonstrating their original derivation
from NPC. Left: phase contrast image at passage 16; Right:
fluorescent image of the same field showing GFP+. Scale bar:
100 mm.
Found at: doi:10.1371/journal.pone.0010357.s004 (1.31 MB
PDF)
Figure S5 Proliferation analysis of NPC-derived tumor cell
cultures (NPC-DTCC). Panel A: long-term proliferation curves for
the 7 established primary cell cultures. The total number of cells
cultured for .200 days in vitro was calculated at each subculturing
passage. Exponential expansion rate was maintained over time
and the total amount of cells, yielded from a starting number of
406103, was 1050 cells for each cell line. Panel B: Relative
increase of NPC-DTCC growth rate was assessed by plotting the
number of cells yielded at each single subculturing passage (from
16 to 32 passages). Curves reveal a modest but constant upward
trend of proliferation rate throughout long-term culturing.
Found at: doi:10.1371/journal.pone.0010357.s005 (0.01 MB
PDF)
Table S1 Tumor formation after islet/NPC co-transplantation
in allogenic and singeneic models.
Found at: doi:10.1371/journal.pone.0010357.s006 (0.05 MB
DOC)
Author Contributions
Conceived and designed the experiments: RM AM MB SP RG VS EB
GM EB CD LP. Performed the experiments: RM BA AM AV CD.
Analyzed the data: BA AV VS CD LP. Contributed reagents/materials/
analysis tools: MB SP RG EB GM CD. Wrote the paper: AV SP CD LP.
References
1. Martino G, Pluchino S (2006) The therapeutic potential of neural stem cells. Nat
Rev Neurosci 7: 395–406.
2. Miller RH (2006) The promise of stem cells for neural repair. Brain Res 1091:
258–264.
3. Pluchino S, Zanotti L, Rossi B, Brambilla E, Ottoboni L, et al. (2005)
Neurosphere-derived multipotent precursors promote neuroprotection by an
immunomodulatory mechanism. Nature 436: 266–271.
4. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, et al. (2003) Injection
of adult neurospheres induces recovery in a chronic model of multiple sclerosis.
Nature 422: 688–694.
5. Ben-Hur T, Einstein O, Mizrachi-Kol R, Ben-Menachem O, Reinhartz E, et al.
(2003) Transplanted multipotential neural precursor cells migrate into the
inflamed white matter in response to experimental autoimmune encephalomy-
elitis. Glia 41: 73–80.
6. Einstein O, Karussis D, Grigoriadis N, Mizrachi-Kol R, Reinhartz E, et al.
(2003) Intraventricular transplantation of neural precursor cell spheres
attenuates acute experimental allergic encephalomyelitis. Mol Cell Neurosci
24: 1074–1082.
7. Einstein O, Fainstein N, Vaknin I, Mizrachi-Kol R, Reihartz E, et al. (2007)
Neural precursors attenuate autoimmune encephalomyelitis by peripheral
immunosuppression. Ann Neurol 61: 209–218.
8. Pluchino S, Zanotti L, Brambilla E, Rovere-Querini P, Capobianco A, et al.
(2009) Immune regulatory neural stem/precursor cells protect from central
nervous system autoimmunity by restraining dendritic cell function. PLoS One
4: e5959.
9. Lee ST, Chu K, Jung KH, Kim SJ, Kim DH, et al. (2008) Anti-inflammatory
mechanism of intravascular neural stem cell transplantation in haemorrhagic
stroke. Brain 131: 616–629.
10. Wang L, Shi J, van Ginkel FW, Lan L, Niemeyer G, et al. (2009) Neural stem/
progenitor cells modulate immune responses by suppressing T lymphocytes with
nitric oxide and prostaglandin E2. Exp Neurol 216: 177–183.
11. Fainstein N, Vaknin I, Einstein O, Zisman P, Ben Sasson SZ, et al. (2008)
Neural precursor cells inhibit multiple inflammatory signals. Mol Cell Neurosci
39: 335–341.
12. Lu Z, Hu X, Zhu C, Wang D, Zheng X, et al. (2009) Overexpression of CNTF in
Mesenchymal Stem Cells reduces demyelination and induces clinical recovery in
experimental autoimmune encephalomyelitis mice. J Neuroimmunol 206: 58–69.
13. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, et al. (2005)
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyeli-
tis inducing T-cell anergy. Blood 106: 1755–1761.
14. Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, et al. (2005)
Transplantation of umbilical-cord blood in babies with infantile Krabbe’s
disease. N Engl J Med 352: 2069–2081.
15. Robertson RP (2004) Islet transplantation as a treatment for diabetes - a work in
progress. N Engl J Med 350: 694–705.
16. Marzorati S, Pileggi A, Ricordi C (2007) Allogeneic islet transplantation. Expert
Opin Biol Ther 7: 1627–1645.
17. Solari MG, Srinivasan S, Boumaza I, Unadkat J, Harb G, et al. (2009) Marginal
mass islet transplantation with autologous mesenchymal stem cells promotes
long-term islet allograft survival and sustained normoglycemia. J Autoimmun 32:
116–124.
18. Sordi V, Melzi R, Mercalli A, Formicola R, Doglioni C, et al. (2010)
Mesenchymal cells appearing in pancreatic tissue culture are bone marrow-
derived stem cells with the capacity to improve transplanted islet function. Stem
Cells 28: 140–151.
19. Mineo D, Ricordi C, Xu X, Pileggi A, Garcia-Morales R, et al. (2008)
Combined islet and hematopoietic stem cell allotransplantation: a clinical pilot
trial to induce chimerism and graft tolerance. Am J Transplant 8: 1262–
1274.
20. Battaglia M, Stabilini A, Draghici E, Gregori S, Mocchetti C, et al. (2006)
Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that
mediate antigen-specific transplantation tolerance. Diabetes 55: 40–49.
21. Foroni C, Galli R, Cipelletti B, Caumo A, Alberti S, et al. (2007) Resilience to
transformation and inherent genetic and functional stability of adult neural stem
cells ex vivo. Cancer Res 67: 3725–3733.
22. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, et al. (2006)
Accumulated chromosomal instability in murine bone marrow mesenchymal
stem cells leads to malignant transformation. Stem Cells 24: 1095–1103.
23. Burns JS, Abdallah BM, Guldberg P, Rygaard J, Schroder HD, et al. (2005)
Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures
of telomerase-immortalized human mesenchymal stem cells. Cancer Res 65:
3126–3135.
24. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, et al.
(2005) Spontaneous human adult stem cell transformation. Cancer Res 65:
3035–3039.
25. Shiras A, Chettiar ST, Shepal V, Rajendran G, Prasad GR, et al. (2007)
Spontaneous transformation of human adult nontumorigenic stem cells to
cancer stem cells is driven by genomic instability in a human model of
glioblastoma. Stem Cells 25: 1478–1489.
26. Reynolds BA, Rietze RL (2005) Neural stem cells and neurospheres–re-
evaluating the relationship. Nat Methods 2: 333–336.
27. Morshead CM, Benveniste P, Iscove NN, van der Kooy D (2002) Hematopoietic
competence is a rare property of neural stem cells that may depend on genetic
and epigenetic alterations. Nat Med 8: 268–273.
28. van der Heide LP, Ramakers GM, Smidt MP (2006) Insulin signaling in the
central nervous system: learning to survive. Prog Neurobiol 79: 205–221.
NPC and Pancreatic Islets
PLoS ONE | www.plosone.org 11 April 2010 | Volume 5 | Issue 4 | e1035729. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, et al. (1993)
Treatment and prevention of rat glioblastoma by immunogenic C6 cells
expressing antisense insulin-like growth factor I RNA. Science 259: 94–97.
30. Martin DM, Yee D, Carlson RO, Feldman EL (1992) Gene expression of the
insulin-like growth factors and their receptors in human neuroblastoma cell lines.
Brain Res Mol Brain Res 15: 241–246.
31. Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M (1992)
Expression of insulin-like growth factors I and II and their receptor mRNAs
in primary human astrocytomas and meningiomas; in vivo studies using in situ
hybridization and immunocytochemistry. Int J Cancer 50: 215–222.
32. Arcaro A, Doepfner KT, Boller D, Guerreiro AS, Shalaby T, et al. (2007) Novel
role for insulin as an autocrine growth factor for malignant brain tumour cells.
Biochem J 406: 57–66.
33. Beyer M, Schultze JL (2009) Regulatory T cells: major players in the tumor
microenvironment. Curr Pharm Des 15: 1879–1892.
34. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific
recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege
and predicts reduced survival. Nat Med 10: 942–949.
35. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, et al. (2002)
Prevalence of regulatory T cells is increased in peripheral blood and tumor
microenvironment of patients with pancreas or breast adenocarcinoma.
J Immunol 169: 2756–2761.
36. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, et al. (2006)
Increased regulatory T-cell fraction amidst a diminished CD4 compartment
explains cellular immune defects in patients with malignant glioma. Cancer Res
66: 3294–3302.
37. Melzi R, Battaglia M, Draghici E, Bonifacio E, Piemonti L (2007) Relevance of
hyperglycemia on the timing of functional loss of allogeneic islet transplants:
implication for mouse model. Transplantation 83: 167–173.
38. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, et al. (2006)
International trial of the Edmonton protocol for islet transplantation.
N Engl J Med 355: 1318–1330.
39. Gritti A, Parati EA, Cova L, Frolichsthal P, Galli R, et al. (1996) Multipotential
stem cells from the adult mouse brain proliferate and self-renew in response to
basic fibroblast growth factor. J Neurosci 16: 1091–1100.
NPC and Pancreatic Islets
PLoS ONE | www.plosone.org 12 April 2010 | Volume 5 | Issue 4 | e10357